Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Personalized (or precision) medicine promises to use genomic information to improve the prevention, diagnosis, and treatment of disease. This promise is particularly anticipated in the arena of cancer treatment. Cancer centers and commercial laboratories are rapidly developing programs to routinely analyze individual cancer genomes to identify therapeutic targets and individualize care.1 However, the process of decoding the genome of a patient’s tumor may incidentally reveal information about inherited predispositions to cancer and other diseases (the “incidentalome”). There is a need to establish approaches to decision making with respect to the return of these incidental results.
Bombard Y, Robson M, Offit K. Revealing the Incidentalome When Targeting the Tumor Genome. JAMA. 2013;310(8):795-796. doi:10.1001/jama.2013.276573